Stock

This biotech company is hard at work to win the coronavirus vaccine race. Will it succeed? All eyes are on the drug manufacturers that are racing to develop the first safe and efficacious coronavirus vaccine. Global COVID-19 cases have crossed the 15 million mark, with at least 634,000 deaths worldwide. In the United States alone,…

A flare-up of U.S.-China tensions shouldn't distract investors from the longer-term story. What happened Shares of electric-vehicle maker NIO (NYSE:NIO) and other Chinese stocks were moving lower on Wednesday, on investor fears of a flare-up of international tensions after the U.S. government ordered the closure of China's consulate in Houston. As of 11:30 a.m. EDT,…

In this episode of MarketFoolery, host Chris Hill chats with analyst Emily Flippen about the latest quarterly results and news from Wall Street. They talk about why Moderna (NASDAQ:MRNA) is facing backlash from some quarters around its COVID-related announcements. Another healthcare provider posted robust earnings, beating market expectations. Also, Emily shares a stock to keep…

U.S. equity futures are trading higher ahead of the Wednesday Wall Street session following promising news about an experimental vaccine for the coronavirus.The major futures indexes are suggesting a gain of 1.3 percent.GET FOX BUSINESS ON THE GO BY CLICKING HEREInvestors were encouraged by news that an experimental COVID-19 vaccine under development by Moderna and…

Published: July 14, 2020 at 6:23 p.m. ET New study shows ‘robust’ immune response to trial vaccine, Moderna says Moderna headquarters in Cambridge, Mass. Getty Images Moderna Inc. stock skyrocketed in the extended session Tuesday after the biotech company said its coronavirus vaccine candidate produced a “robust” immune-system response in a larger group of people…